Joshua Makower has dedicated his life to the creation of medical technologies which improve the quality of life for patients. He is the CEO and Founder of ExploraMed Development, LLC, a medical device incubator based on the West Coast. He is also a Venture Partner with New Enterprise Associates where he supports the investing activity in the medical device arena. Josh serves as a Consulting Associate Professor of Medicine at Stanford University Medical School and co-founded Stanford’s Biodesign Innovation Program. A compendium of the materials created to support the teaching efforts in the Stanford Biodesign program has recently been published under the Cambridge University text title of: Biodesign: The Process of Innovating New Medical Technologies. Josh has founded several companies through the ExploraMed incubator which have achieved successful M&A transactions including Acclarent, Inc., a company focused on developing novel therapies in ENT, which was acquired by J&J in 2010, TransVascular, Inc., a company focused on the development of a completely catheter-based coronary bypass technology, which was acquired by Medtronic, Inc. in 2003, and EndoMatrix, Inc., a company focused on the development of a novel therapy for incontinence and GI Reflux, which was acquired by C.R. Bard in 1997. Up until 1995, Josh was Founder and Manager of Pfizer’s Strategic Innovation Group, a group chartered to create new medical device technologies and businesses for Pfizer’s medical device businesses. Josh also serves on the Board of Directors for NeoTract, Inc,, Moximed, Inc., Intrinsic Therapeutics, Inc., ExploraMed III, Inc. and Vibrynt, Inc. Josh holds over five dozen patents for various medical devices in the fields of Orthopedics, ENT, Cardiology, General Surgery, Drug Delivery and Urology. Josh holds an M.B.A. Columbia University, an M.D. from the New York University School of Medicine, and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.